Clinical Trial

Prostate Cancer Biomarker Enrichment and Treatment Selection

Study Description

Prostate Cancer Biomarker Enrichment and Treatment Selection

The purpose of the pre-study screening is to test for DNA abnormalities or biomarkers.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Adavosertib

300mg days 1-5, 8-12 q21 days

Drug - Savolitinib

300mg once daily, orally.

Drug - Darolutamide

600mg twice daily, orally.

Drug - CFI-400945

Dose level assigned at enrollment on 1 wk on and 1 wk off. Cycle 1 will consist of a 14-day run-in with CFI-400945 at 48 mg/day for 7 days and followed by a 7-day period without CFI-400945 administration.

Drug - Ipatasertib

400mg daily 3 weeks on, 1 week off

Drug - Durvalumab and Tremelimumab

Durvalumab 1500mg day 1 every 4 weeks; Tremelimumab 225mg day 1 cycle 1

Additional Information

Official Study Title

Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study

Clinical Trial ID

NCT03385655

ParticipAid ID

qaQ4Me